Dichlorvos (DDVP) Risk Characterization Document - California ...
Dichlorvos (DDVP) Risk Characterization Document - California ...
Dichlorvos (DDVP) Risk Characterization Document - California ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Table 2.<br />
Selected no-observed-effect levels (NOELs) and lowest-observed-effect levels (LOELs) of <strong>DDVP</strong> for sublethal acute effects from acute<br />
studies.<br />
Plasma ChE a RBC ChE a Brain ChE a Other Effects<br />
Species Route Duration a NOEL LOEL % C NOEL LOEL % C NOEL LOEL % C NOEL LOEL Effects Ref. b<br />
(mg/kg-day) (mg/kg-day) (mg/kg-day) (mg/kg-day)<br />
Rat c gavage 1 dose >30 no effect - 30 d 47-91% - - 9 13 irritability, salivation, 1<br />
diarrhea, tremors<br />
Rat gavage 1 dose - - - - - - 0.5 1.0 gait alteration 2<br />
Rat gavage 1 dose - - - - - - 0.5 35 gait alteration, pupillary 3<br />
constriction, tremors, and others<br />
Rat e gavage d6-15 - - - - - - 3 21 tremors after each dosing 4*<br />
gestation<br />
Chicken f oral 1 dose - - - - - - - 16.5 d nerve fiber degeneration, 5<br />
axonal swelling<br />
Rat inhal 4 h - - - - - - 8 14 lethargy, pupillary constriction 6<br />
Rabbit e inhal d1-28 - - - - - - 0.65 1.0 death in 2-3 days 7<br />
Human inhal 18h/dx5d >0.07 no effect >0.07 no effect - - >0.07 no effect 8<br />
new born<br />
Human inhal 24h/dx1-5d 9<br />
men without liver disease 0.02 0.031 28-65% >0.031 no effect - - >0.031 no effect<br />
men with liver disease - 0.006 35-67% >0.006 no effect - - >0.006 no effect<br />
women (labor and postpartum) >0.026 no effect >0.026 no effect - - >0.026 no effect<br />
sick children 0.014 0.02 55-92% >0.02 no effect - - >0.02 no effect<br />
a/<br />
b/<br />
c/<br />
d/<br />
e/<br />
f/<br />
Abbreviations: ChE=cholinesterase, RBC=erythrocyte, inhal=inhalation, h=hours, d=days, % C=% of control values at the LOEL, -=data not available.<br />
* after the reference number indicates the study was acceptable according to FIFRA guidelines. References: 1. Tracy et al., 1960; 2. Lamb, 1992; 3.<br />
Lamb, 1993a; 4. Tyl et al., 1991a; 5. Beavers et al., 1988; 6. Blair et al., 1975; 7. Thorpe et al., 1971b; 8. Cavagna et al., 1970; and 9. Cavagna et al.,<br />
1969.<br />
The study is described in III.C. SUBCHRONIC TOXICITY.<br />
The only concentration tested, not necessarily the LOEL.<br />
The study is described in III.G. DEVELOPMENTAL TOXICITY.<br />
The study is described in III.H. NEUROTOXICITY.<br />
24